AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

AnaptysBio, Inc. 10770 Wateridge Circle Suite 210 San Diego, CA 92121-5801 . Phone: (858) 362-6295 [email protected]

AnaptysBio, Inc. 10770 Wateridge Circle Suite 210 San Diego, CA 92121-5801 (858) 362-6295 (ph) [email protected]

SAN DIEGO , Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga , president and chief executive officer of Anaptys, will present at the 43 rd Annual J.P.

Immune cell modulators are a novel therapeutic class with the potential to deliver differentiated outcomes in autoimmune and inflammatory diseases including dermatology, gastroenterology, and rheumatology

Rosnilimab is a novel PD-1 agonist that reduces overactive T cell inflammation. It has two distinct mechanisms of action, depletion and agonism, prevalent both in inflamed tissue and the periphery, targeting PD-1+ T cells broadly impacting multiple drivers of disease pathogenesis

We never conduct our interview process via messaging apps, freelance sites or social media platforms (i.e., Google Hangouts, WhatsApp, Signal, etc.). We only communicate with potential candidates through an official Anaptys email address ending in “@anaptysbio.com.”

Feb 3, 2025 · WASHINGTON and SAN DIEGO, Feb. 3, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully completed …

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 ...

Anaptys Announces Positive Top-Line Phase 3 Clinical ... - AnaptysBio, Inc.